GlassScriptPhysician profile
Andro N Sharobiem
NPI 1073711453
$10,181.67
in general payments reported to CMS, 2019-2025
54 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $749 · 2021: $1,694 · 2022: $1,539 · 2023: $1,787 · 2024: $849 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,583 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,583.02 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $903.57 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $732.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $629.31 | 2019-2025 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $591.52 | 2020-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.45 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $500.65 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $423.73 | 2019-2025 | |
| Astellas Pharma US INC | $415.04 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $408.41 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $366.63 | 2021-2025 | |
| Amgen INC. | $355.78 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $336.32 | 2019-2025 | |
| Ucb, INC. | $289.11 | 2021-2022 | |
| Allergan, INC. | $260.56 | 2019-2020 | |
| Lilly USA, LLC | $253.20 | 2020-2025 | Jardiance, Mounjaro, Emgality |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andro Sharobiem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.